Long-term human response following subretinal injection of recombinant adenoassociated virus-sFlt-1 vector

视网膜下注射重组腺相关病毒-sFlt-1载体后的长期人体反应

• 批准号: nhmrc : 1010405
• 负责人: Dr Chooi-May Lai
• 金额: $ 24.88万
• 依托单位: The University of Western Australia
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/long-term-human-1-vector/109489
• 关键词: Long; term; human; response; following

Age-related Macular Degeneration (AMD) is the major cause of blindness in the developed world. The present best practice for treating wet AMD is monthly injections of Lucentis� into the eye which is expensive, inconvenient for the patient and has increased risk of infection. The additional assays associated with the clinical trial will test whether adeno-associated virus-mediated gene therapy is safe and whether it can eliminate the need of multiple injections while delivering the same outcome.

年龄相关性黄斑变性（AMD）是发达国家致盲的主要原因。目前治疗湿性黄斑变性的最佳做法是每月向眼部注射Lucentis，这是昂贵的，对患者不方便，并且增加了感染的风险。与临床试验相关的其他分析将测试腺相关病毒介导的基因治疗是否安全，以及它是否可以在提供相同结果的同时消除多次注射的需要。